NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Toviaz™ (fesoterodine fumarate) extended release tablets and the YourWay™ plan (www.ToviazYourWay.com), a comprehensive, customizable support plan for overactive bladder patients, are available in the United States. Toviaz is a once-daily prescription treatment for patients with symptoms of overactive bladder, which include frequent and sudden urges to urinate and wetting accidents. Toviaz works by helping to calm the bladder muscle that causes frequent, sudden urges to urinate.
